Strategic partnerships Patheon, as Thermo Fisher’s pharmaceutical services CDMO, emphasizes strategic partnerships and end-to-end solutions across development, clinical, and commercial stages. This positions it well for sales pitches that highlight collaborative models, risk sharing, and integrated supply chains with biotech and pharma companies seeking streamlined outsourcing.

Global scale With more than 60 locations worldwide and a broad service footprint including API, biologics, viral vectors, formulation, and logistics, Patheon can support multinational programs and regional manufacturing needs. Leverage this to target companies pursuing global trials or nearshoring/onsite scale-up.

Expansion momentum Recent facility expansions and new collaborations, such as the Mebane manufacturing expansion and partnerships with Ethris, Cybin, RoosterBio, MiraiBio, and others, signal growth and capacity investments. Use this to frame opportunities in high-demand areas like gene therapy, cell therapy, and complex biologics manufacturing.

Flexible manufacturing PharmaFlex launched in 2024 as a flexible platform for biologics, small molecules, and complex formulations, aligning with customers needing adaptable production capacity. This can be marketed to startups and late-stage companies requiring scalable, configurable manufacturing solutions.

Tech-enabled service A tech stack featuring cloud, CRM, marketing automation, and analytics tools indicates a modern, data-driven customer experience. Sales teams can leverage digital touchpoints and insights to engage prospects, tailor proposals, and optimize trial-to-commercial timelines across geographies.